Is Aurora Cannabis Inc. (TSX:ACB) Firing on All Cylinders or Taking the Corner Way Too Fast?

In the proverbial race to become the biggest dog in the fight for Canada’s top spot as cannabis king, Aurora Cannabis Inc.  (TSX:ACB) continues to amaze with acquisition followed by acquisition.

Fundamentally, the acquisition of cannabis producers at this stage in the game still makes sense for companies relying on all-stock deals. As Aurora’s stock price continues to climb, trading shares in the company for shares in the acquired firm only dilutes existing shareholders, but it does not impact cash on the firm’s balance sheet — cash which is becoming increasingly scarce. With equity markets expected to continue to remain robust for the foreseeable future, relying on appreciating equity to fund acquisitions can result in more acquisitions for companies like Aurora in the near to medium term.

Keeping up its torrid pace, Aurora’s management team has recently announced yet another “small” acquisition — this time the $115 million buyout of Anandia Laboratories, a small cannabis-focused laboratory business in Vancouver, B.C. This acquisition brings new capabilities to Aurora’s business operations, allowing the company to delve deeper into R&D and testing for the company’s product.

On some level, this acquisition actually might make sense in the long run for a company like Aurora for a couple of key reasons. First, as marijuana becomes legalized on the federal level in Canada, expect to see additional testing requirements for producers from Health Canada. In order to produce marijuana, companies like Aurora are required to do regular testing with firms such as Anandia. Bringing this expertise in-house could bode well for the firm in getting approvals for new value-added products down the road, giving the impression to regulators that Aurora takes its testing very seriously.

This acquisition also opens certain patenting and licensing doors to Aurora. Similar to what other seed companies have done, patenting a specific strain or product infused with cannabis would require some sort of partnership with an operation such as Anandia to really dive into the science behind new products or strains within the cannabis sector. This is uncharted territory, so maybe Aurora got a steal here.

Either way, Aurora’s strategy is piecing together a gigantic firm from a bunch of smaller ones, in effect increasing near- to medium-term integration pressure and costs as we near the legalization horizon. Another all-stock deal, the Anandia addition may add long-term value, but at a significant short-term dilutive cost to shareholders (especially when considering the incredible number of all-stock, or mostly-stock deals, the company has completed recently).

Stay Foolish, my friends.

Our #1 Stock to Buy in 2018 (and Beyond!)

When you buy heavily cyclical stocks at low prices… and then hold the shares until the cycle reaches its peak… you can make a very healthy profit.

Every investor knows that. But many struggle to identify the best opportunities.

Except The Motley Fool may have a plan to solve that problem! Our in-house analyst team has poured thousands of hours into their proprietary research – and this is the result.

Our top advisor Iain Butler has just identified his #1 stock to buy in 2018 (and beyond).

The last time this stock went from the low point of its cycle to the peak… shares shot from $12 to $40 inside of 4 years. That’s an 300%-plus return. And if you missed out on that ride, today might just be your second chance.

Click here to claim Iain’s new report, absolutely FREE!

Fool contributor Chris MacDonald has no position in any stocks mentioned in this article.

I consent to receiving information from The Motley Fool via email, direct mail, and occasional special offer phone calls. I understand I can unsubscribe from these updates at any time. Please read the Privacy Statement and Terms of Service for more information.